GET DAILY SIGNALSMDxHealth (MDXH): Navigating the Steep Climb Toward the $1.00 Analyst Target
Key Takeaways
- The central target of $1.00 is the arithmetic mean of the remaining verifiable analyst price targets on record, which span a wide $0.50 to $1.50 range.
- With shares near $0.14, reaching $1.00 would require a gain of more than 600%, a very large move that reflects how sharply MDxHealth SA (MDXH) has fallen over the past year.
- The $1.00 level also coincides with the Nasdaq minimum-bid compliance threshold, making it the most consequential price level for the stock right now.
- Coverage has thinned rapidly: BTIG and Craig-Hallum withdrew targets entirely and downgraded the stock, while Lake Street cut its target to $0.50 after a Q3 revenue miss.
- The strongest supports are a fast-growing liquid-biopsy (ExoDx) test volume and a recent capital raise; the biggest risks are sales-force attrition, heavy debt, negative equity, and delisting pressure.
- You can explore the ticker's Major News, Today's Price Move, Forecast, and Earnings on additional pages for deeper context.
- For automated market insight, explore Trending AI Robots.
Understanding the Revised Analyst Landscape
MDxHealth SA (MDXH) is a Belgium-headquartered, commercial-stage precision diagnostics company listed on Nasdaq, focused on urologic and prostate-cancer tests such as ConfirmMDx, SelectMDx, and the ExoDx liquid-biopsy franchise. Its analyst coverage has been reset dramatically in 2026 as targets fell from as high as $9 earlier in the year. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The remaining verifiable targets on record span roughly $0.50 to $1.50. The most recent is Lake Street's $0.50 target, issued October 16, 2026, when analyst Thomas Flaten cut his figure from $3.00 and downgraded the stock to Hold. TD Cowen's $1.50 Buy target dates to May 14, 2026 and predates the October revenue miss, while one additional $1.00 target from mid-August remains on record. Averaging these three figures produces a mean of $1.00, which is used as the central target here. Importantly, this is not a well-populated consensus: BTIG withdrew its $2.00 target and moved to Neutral on October 19, and Craig-Hallum downgraded the stock to Hold without a price target on October 16. William Blair had earlier moved to Market Perform. The wide $0.50-to-$1.50 spread reflects genuine disagreement about whether the business can stabilize its sales force and rebuild growth.
Current Market Position and Path Toward the Target
Shares closed at $0.1393 on November 10, 2026, near the low end of a 52-week range of roughly $0.14 to $4.49. Reaching $1.00 from that level would require a gain of approximately 620%, a very large move by any standard. The path is complicated by the fact that the stock collapsed more than 60% in a single week in mid-October after the company pre-announced preliminary third-quarter revenue of $22.7 million, flat year over year and roughly 7.5% below consensus, and suspended its 2026 revenue guidance of $110 million to $115 million. Management attributed the shortfall to unexpected sales-force turnover following the wind-down of its former Resolve urinary-tract-infection test.
Factors That Could Support a Move Higher
There are a few tangible supports. Liquid-based ExoDx test volume rose roughly 2.6-fold year over year in the third quarter, showing that the core prostate-diagnostic franchise retains demand. Second-quarter revenue grew 16% year over year and beat Wall Street estimates, and a $20 million registered direct placement in August extended the cash runway, leaving about $31.7 million in cash at September 30. Because $1.00 is the Nasdaq minimum-bid compliance level, a reverse split or renewed revenue momentum could mechanically or fundamentally restore the share price toward that threshold, although a reverse split creates no value on its own.
Key Risks That Could Keep the Target Out of Reach
The obstacles are substantial. Tissue-based ConfirmMDx and GPS test volume fell 11% year over year, sales-force attrition disrupted forecasting, and the company suspended guidance with less than three months left in the year. The balance sheet is strained: non-current borrowings were about $96.4 million at mid-2026 against a market capitalization of roughly $13 million, with negative total equity. The company received a Nasdaq minimum-bid notice on July 2, 2026, and faces a compliance deadline around late December 2026. An earlier $10.4 million Medicare recoupment dispute and the exit from the Resolve business add further uncertainty, and any additional equity financing could dilute shareholders.
Technical Levels and Market Structure
The $1.00 mark functions as a powerful psychological and regulatory level: it is both the Nasdaq minimum-bid compliance threshold and a former price zone now far above current trading. There is little meaningful near-term support beneath the recent 52-week low near $0.14, while resistance is layered between $0.50 and $1.00. The 52-week high near $4.49 underscores how far the stock has fallen, and the rapid October breakdown suggests the shares are in a state of distressed, high-volatility trading rather than an established uptrend.
Time Horizon and What Investors Should Monitor
Analyst price targets generally reflect a research horizon of roughly 12 months, but for MDXH the more urgent clock is regulatory: the Nasdaq cure period runs to approximately late December 2026. Investors should watch the third-quarter earnings report scheduled for November 12, 2026, any restoration of forward guidance, evidence that sales-force attrition has stopped, ExoDx and tissue-test volume trends, covenant compliance and cash burn, and any reverse-split or financing announcements.
Using AI for Ongoing Market Monitoring
In my routine analysis, Tickeron's AI Daily Buy/Sell Signals have become a useful way to track momentum shifts in names like this. The tool applies artificial intelligence to monitor thousands of stocks and ETFs in real time, producing Buy, Sell, or Hold signals based on technical behavior and market conditions. For a volatile, low-priced stock such as MDXH, these signals can help identify changes in trend without relying solely on manual chart review, allowing traders to stay informed on new opportunities and existing positions more efficiently.
Final Assessment
Can MDXHealth reach $1.00? The question is meaningful partly because $1.00 is the average of the remaining analyst targets ($0.50 to $1.50) and partly because it is the Nasdaq compliance threshold the company must ultimately clear. Reaching it from near $0.14 would require a very large, roughly 620% gain, and the near-term catalysts are heavily weighted toward risk: a revenue miss, withdrawn guidance, sales-force disruption, a leveraged balance sheet, and delisting pressure. The bull case rests on ExoDx volume growth and a stabilized cash position, but with several firms having withdrawn targets entirely, the analyst range is wide and conviction is low. Investors should monitor the November earnings report, guidance, and Nasdaq compliance developments rather than assume any particular outcome.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
MDXH's Stochastic Oscillator is sitting in oversold zone for 16 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 17 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Moving Average Convergence Divergence (MACD) for MDXH just turned positive on November 06, 2026. Looking at past instances where MDXH's MACD turned positive, the stock continued to rise in 22 of 30 cases over the following month. The odds of a continued upward trend are 73%.
Following a +4.57% 3-day Advance, the price is estimated to grow further. Considering data from situations where MDXH advanced for three days, in 96 of 124 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
MDXH may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MDXH as a result. In 39 of 50 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 78%.
MDXH moved below its 50-day moving average on October 14, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MDXH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The Aroon Indicator for MDXH entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 58 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (23.641) is normal, around the industry mean (67.298). P/E Ratio (0.000) is within average values for comparable stocks, (4.239). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (0.301) is also within normal values, averaging (9.775).
The Tickeron Price Growth Rating for this company is 98 (best 1 - 100 worst), indicating slightly worse than average price growth. MDXH’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MDXH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 85, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalSpecialties
Advertisement